Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy by Bandera, Alessandra et al.
RESEARCH ARTICLE
Evaluation of the Prognostic Value of
Impaired Renal Function on Clinical
Progression in a Large Cohort of HIV-Infected
People Seen for Care in Italy
Alessandra Bandera1*, Andrea Gori1, Francesca Sabbatini1, Giordano Madeddu2,
Stefano Bonora3, Raffaella Libertone4, Claudio Mastroianni5, Paolo Bonfanti6,
Antonella d'Arminio Monforte7, Alessandro Cozzi-Lepri8, Icona Foundation Study Group¶
1 Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of
Milano-Bicocca, Monza, Italy, 2 Department of Infectious Diseases, University of Sassari, Sassari, Italy,
3 Department of Infectious Diseases of the University of Torino, Amedeo di Savoia Hospital, Torino, Italy,
4 National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy, 5 Department of Infectious and
Tropical Diseases, Sapienza University, Polo Pontino, Latina, Italy, 6 Infectious Diseases Unit, Alessandro
Manzoni Hospital, Lecco, Italy, 7 Clinic of Infectious Diseases and Tropical Medicine, University of Milan,
San Paolo Hospital, Milan, Italy, 8 University College London, London, United Kingdom
¶ Membership of the Icona Foundation Study Group is listed in the Acknowledgments.
* alessandra.bandera@unimib.it
Abstract
Whilst renal dysfunction, especially mild impairment (60<eGFR<90 ml/min), has been often
described in HIV-infected population, its potential contribution to HIV evolution and risk of
cerebro-cardiovascular disease (CCVD) has not been clarified. Data from HIV-1 infected
patients enrolled in the Italian Cohort of Antiretroviral-Naïve (Icona) Foundation Study col-
lected between January 2000 and February 2014 with at least two creatinine values avail-
able. eGFR (CKD-epi) and renal dysfunction defined using a priori cut-offs of 60 (severely
impaired) and 90 ml/min/1.73m2 (mildly impaired). Characteristics of patients were de-
scribed after stratification in these groups and compared using chi-square test (categorical
variables) or Kruskal Wallis test comparing median values. Follow-up accrued from base-
line up to the date of the CCVD or AIDS related events or death or last available visit. Kaplan
Meier curves were used to estimate the cumulative probability of occurrence of the events
over time. Adjusted analysis was performed using a proportional hazards Cox regression
model. We included 7,385 patients, observed for a median follow-up of 43 months (inter-
quartile range [IQR]: 21-93 months). Over this time, 130 cerebro-cardiovascular events (in-
cluding 11 deaths due to CCVD) and 311 AIDS-related events (including 45 deaths) were
observed. The rate of CCVD events among patients with eGFR >90, 60-89, <60 ml/min,
was 2.91 (95% CI 2.30-3.67), 4.63 (95% CI 3.51-6.11) and 11.9 (95% CI 6.19-22.85) per
1,000 PYFU respectively, with an unadjusted hazard ratio (HR) of 4.14 (95%CI 2.07-8.29)
for patients with eGFR <60 ml/min and 1.58 (95%CI 1.10-2.27) for eGFR 60-89 compared
to those with eGFR90. Of note, these estimates are adjusted for traditional cardio-
vascular risk factors (e.g. smoking, diabetes, hypertension, dyslipidemia). Incidence of
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AIDS-related events was 9.51 (95%CI 8.35-10.83), 6.04 (95%CI 4.74-7.71) and 25.0 (95%
CI 15.96-39.22) per 1,000 PYFU, among patients with eGFR >90, 60-89, <60 ml/min, re-
spectively, with an unadjusted HR of 2.49 (95%CI 1.56-3.97) for patients with eGFR <60 ml/
min and 0.68 (95%CI 0.52-0.90) for eGFR 60-89. The risk of AIDS events was significantly
lower in mild renal dysfunction group even after adjustment for HIV-related characteristics.
Our data confirm that impaired renal function is an important risk marker for CCVD events in
the HIV-population; importantly, even those with mild renal impairment (90<eGFR<60)
seem to be at increased risk of cerebro-cardiovascular morbidity and mortality.
Introduction
HIV infected individuals, because of the availability of effective and well tolerated antiretroviral
treatments (ART), show considerably prolonged survival and are now facing a new set of
health challenges. Several studies have addressed non-HIV related diseases in HIV-positive
population, identifying aging, antiretroviral treatments and HIV itself as leading causes of
premature atherosclerosis vascular disease leading to increased cardiovascular disease mortali-
ty in these patients [1]. Accumulated evidence in the general population suggests that reduced
kidney function exposes patients to an increased rate of cerebro-cardiovascular disease
(CCVD) both in populations at high risk for CCVD and even in the absence of traditional risk
factors [2–3].
Proportion of patients with HIV infection and renal impairment of any grade are variable in
published studies, ranging between 5% and up to 32% in some cases and mostly represented by
mild renal dysfunction (90<eGFR<60 ml/min) [4–7]. Mild renal dysfunction is also frequent
in HIV-infected population seen for care in Italy with a prevalence of 25% in ART-naïve pa-
tients [8].
Previous analysis that investigated the association between kidney disease and the risk of
CCVD in HIV-population showed that both an eGFR less than 60 ml/min and albuminuria
were associated with higher risk of CCVD and heart failure [9]. Moreover, severe renal dys-
function has been associated with increased risk of HIV disease progression and even death in
several studies [10–13]. However, most of these studies evaluated patients not receiving ART
or they have been conducted in the early highly active antiretroviral therapy era [9], thus con-
cerning settings with a greater incidence of AIDS events. These studies often involve popula-
tions of patients living in settings where antiretroviral treatments are not largely available or
there is limited access to healthcare [11–12], such as sub-Saharian Africa, exposing people to a
greater risk of HIV progression. In addition, none of these studies focused on mild renal dys-
function and its predictive role on clinical outcome has not been assessed.
We, therefore, aimed to use the data of patients enrolled in the Icona Foundation Study to
evaluate the prognostic value of reduced eGFR (both<60 ml/min and 60–90 ml/min) in pre-
dicting the occurrence of CCVD, AIDS defining diseases and consequent deaths over prospec-
tive follow-up.
Methods
Patient population
This analysis includes data from HIV-1 infected patients enrolled in the Italian Cohort of Anti-
retroviral-Naïve Patients (Icona) Foundation Study and collected after January 2000 (date of
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routine collection of creatinine for all patients). All information recorded in the database up to
February 1st 2014. According to protocol inclusion criteria, patients had to be> 18 years old
and start ART when they were naïve to antiretrovirals. In addition, for inclusion in this analy-
sis, they had to have at least two creatinine values available after January 2000.
The ICONA Foundation Study is an Italian multi-centric prospective observational cohort
study of HIV-1-positive persons enrolled since 1997. CD4+ T cell count, HIV-1-RNA, HCV
antibody, HBV surface antigen and antibody and creatinine are systematically recorded every 6
months. Creatinine is measured using a method traceable to IDMS (upper limit of normal 1.3
mg/dL) at the local laboratories of the various sites. Clinical and laboratory data and data re-
garding any drug taken by the patient, either antiretroviral or else, are collected for all partici-
pants and recorded using an electronic data collection form (www.iconafoundation.it). All data
are updated at the occurrence of any clinical event and, in the absence of such an event, at least
every 6 months. AIDS-defining diseases and CCVD events captured by medical record abstrac-
tion are recorded in the database at the date that this diagnosis is confirmed.
The eGFR was used to identify patients in the cohort with potential renal dysfunction. To
better estimate renal function, eGFR was calculated using the CKD-epi formula:GFR = 141 X
min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black]. Where Scr
is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is −0.329 for females and
−0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum
of Scr/κ or 1.
This method of calculation recently emerged as a useful filtration marker even in HIV posi-
tive population, because of reducing bias for all traditional cardiovascular risk factors [14–16].
All individuals signed an informed consent prior to enrollment and the study was
approved by the Ethics Committee of each participating institution that are listed in the
Acknowledgments.
Outcome
The outcomes of interest were the occurrence of newly diagnosed cerebro-cardiovascular
events or AIDS-related events. Only the first of these diagnoses were counted as events and re-
lapses have been ignored in the analysis. The cerebro-cardiovascular endpoint included the fol-
lowing events: angioplasty, coronary artery bypass, cardiac arrhythmia, cerebral haemorrhage,
carotid endarterectomy, cerebral stroke, dilated cardiomyopathy, other cardiac surgical proce-
dures, death due to cardiovascular events. HIV-related events were defined as the occurrence
of a new AIDS-related opportunistic infections or neoplasms (as defined by the Center for Dis-
ease Control and Prevention 1993 classification) and occurrence of AIDS-related deaths.
Statistical analysis
Baseline was defined as the date of the first of the two consecutive creatinine values measured
after January 2000. Patients were grouped according to eGFR values calculated at baseline
using the a priori defined cut-offs of 60 (severely impaired, if at least one value< 60 ml/min)
and 90 ml/min/1.73m2 (mildly impaired, if at least two values between 60–89 ml/min). Charac-
teristics of patients were described after stratification in these groups and compared using chi-
square test (categorical variables) or Kruskal-Wallis test comparing median values (quantita-
tive measures).
Follow-up accrued from baseline up to the date of the event of interests or last available clin-
ical follow-up visit. Rates of events have been calculated as number of new diagnoses occurring
after baseline divided by number of person years of follow-up (PYFU). Confidence intervals
for these estimates were calculated using a Poisson approximation.
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Survival analysis has also been employed. Kaplan Meier curves were used to estimate the cu-
mulative probability of occurrence of the events by longer time from baseline. Log-rank test
was used to compare survival of patients according to different eGFR strata. A multivariable
Cox regression analysis was performed to control for confounding. A sequential manual ad-
justment was used so that estimates were first adjusted for demographic factors (i.e. age, gen-
der, mode of HIV transmission, nationality and calendar year at baseline). Then they were
further adjusted for other set of covariates such as traditional risk factors for CCVD disease
and other clinical parameters (i.e. smoking, diabetes, use of blood pressure and lipids lowering
drugs, total cholesterol, blood glucose and high density lipoprotein cholesterol [HDL]). Finally
a further adjustment was made by adding virus- host- and treatment—related factors such as
use of ART, baseline CD4, CD8 count and nadir CD4 count, HIV RNA and co-infection with
HBC/HCV into the model. Unless noted, only baseline values of time-varying covariates were
included in the model. Relative hazards of cardiovascular disease according to defined eGFR
strata have been estimated and tabulated together with 95% confidence intervals. eGFR was
also examined in the log10 scale because the distribution was skewed in the raw scale. All statis-
tics were 2-sided and a p-value0.05 was considered as significant. SAS version 9.3 was used
for all analyses.
Results
Study population
Seven thousand three hundred eighty-five patients were included in the study and observed
over a median follow-up of 43 months (inter-quartile range [IQR]: 21–93 months).
According to baseline eGRF, patients were stratified in 3 different groups: 5,243 patients
(70.9%) had normal renal function (eGFR>90 ml/min), 1,936 patients (26.2%) had mild
renal impairment (eGFR between 60–89 ml/min in at least two consecutive measures) and 206
patients (2.7%) showed reduced renal function (eGRF<60 ml/min) at this single baseline
measurement.
Median age was 36 years (IQR 31–42), 26.6% of patients were females, HIV transmission
was mainly by heterosexual intercourses (40.1%). Non-Caucasian patients were poorly repre-
sented in our cohort (4.4%). Only a few patients had an AIDS diagnosis prior to the enrollment
in the study (12.3%), consistently with the nadir of CD4+ T cells count (342/μl, IQR: 183–508).
Comparing the 3 categories of patients according to baseline eGFR, a previous AIDS diagnosis
was more frequent in patients with reduced renal function (29.1% and 12.9% among those
with eGFR<60 ml/min and90 ml/min, respectively, p<0.001). Despite the small representa-
tion of patients with a previous diagnosis of cerebro-cardiovascular disease (8.9%), the propor-
tion was higher in participants showing greater reduction in renal function (27.2%, 11.5% and
7.2% among those with eGFR<60, 60–89,90 ml/min, respectively, p<0.001). Patients with
reduced renal function showed a lower median CD4 T cells count (361 [124–551], 453 [270–
660], 449[288–646] cells/μl among those with eGFR<60, 60–89,90 ml/min, respectively,
p<0.001), and a lower nadir CD4 T cells count (200 [57–400], 340 [175–502], 348 [192–514]
cells/μl in the eGFR<60, 60–89 and90 ml/min groups, respectively, p<0.001). People with
lower eGFR were also less likely to be ART-naïve (28.6%, 26.9%, 24.8% in eGFR<60, 60–89,
>90 ml/min groups, respectively, p<0.001). Of note, HIV-infected patients with the worse
baseline eGFR values also showed a higher prevalence of traditional cerebro-cardiovascular
risk factors, such as diabetes (7.8% and 1.6% among those with eGFR<60 and90 ml/min, re-
spectively, p<0.001), hypertension (12.1% versus 2.0% among those with eGFR<60 and90
ml/min, respectively, p<0.001) and dyslipidemia (total cholesterol median values 179 [145–
215] and 167 [141–196] mg/dl among patients with eGFR<60 and90 ml/min, respectively,
Prognostic Value of Impaired Renal Function in HIV Infection
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p<0.001; HDL cholesterol median level 37 [29–49] and 42 [34–52] mg/dl in patients with
eGFR<60 and90 ml/min, respectively, p = 0.002). All characteristics of the patients strati-
fied by baseline eGFR are reported in Table 1.
Rates of cerebro-cardiovascular and AIDS-related events
Over follow-up, 130 cerebro-cardio-vascular events were observed, of whom 11 were deaths
for CCVD (10%), 64 (49.2%) were referable to coronaropathy, 13 (10%) were cerebro-vascular
events, 28 (21.5%) were cardiomyopathy and heart failure and 14(10%) classified as other
major CCVD events, including coronary artery bypass graft, carotid endarterectomy, or
angioplasty.
Patients were followed-up for a total of 35,968 years for an overall incidence of cerebro-
cardiovascular events of 3.6 (95% CI: 3.0–4.3) events per 1,000 PYFU. During study follow-up,
311 AIDS-events occurred, of whom 45 (14.5%) were AIDS-related deaths. In this analysis a
total follow-up of 35,393 years were accumulated for an overall incidence of AIDS-related
events of 8.8 (95% CI:7.8–9.8) events per 1,000 PYFU. A description of the type of cardiovascu-
lar and HIV-related events is reported in Table 2.
Impaired renal function and risk of cardiovascular events
According to the three groups with increasing severity of renal dysfunction, we observed a step-
wise increase in the rate of cerebro-cardiovascular events, as reported in Table 3. Incidence was
2.91 (95% CI 2.30–3.67), 4.63 (95% CI 3.51–6.11) and 11.9 (95% CI 6.19–22.85) per 1,000
PYFU, among patients with eGFR90, 60–89,<60 ml/min, respectively (Fig 1). In the unad-
justed analysis, the incidence rates among patients with reduced renal function (eGFR<60 ml/
min) and mild renal impairment (60<eGFR<90 ml/min) were significantly higher than
among HIV-infected subjects with normal renal function (eGFR90 ml/min), with an unad-
justed hazard ratios (HR) of 4.14 (95%CI 2.07–8.29) and 1.58 (95%CI 1.10–2.27). When we
evaluated eGFR as a continuous variable we found an unadjusted risk of 5.32 (95%CI 3.02–
9.38) per log10 lower eGFR which remained independently associated with higher risk of
CCVD in a multivariate model (adjusted HR 3.28; 95%CI 1.47–7.31) including demographic
characteristics of patients (age, gender, mode of HIV transmission, nationality and calendar
year of baseline), in a second model (adjusted HR 3.71; 95%CI 1.49–9.28) further adjusted for
traditional cardio-vascular risk factors (smoking, diabetes, previous AIDS diagnosis, hyperten-
sion, lipid lowering drugs, total cholesterol, blood glucose levels, HDL cholesterol), and also in
a third model (adjusted HR 7.24; 95%CI 3.05–17.23) further adjusted for HIV-associated char-
acteristics (ART-status, baseline CD4+ and CD8+ T cells count, nadir CD4+ T cell count, base-
line HIV-RNA, co-infection with HCV/HBV).
Similarly, mild renal impairment (90<eGFR<60 ml/min) was associated with an increased
risk of cerebro-cardiovascular event development (adjusted HR 1.72; 95%CI 1.11–2.66) in the
multivariable model adjusted for traditional cardio-vascular risk factors and also after adjust-
ment for HIV associated characteristics (adjusted HR 1.63; 95%CI 1.11–2.40).
Other covariates which resulted independently associated with the risk of CCVD events
were: age (HR 1.78 per 10 years older; 95% CI 1.39–2.30) and ethnicity (HR 4.82 black versus
Caucasian; 95% CI 1.91–12.16) (Table 4).
Impaired renal function and risk of AIDS-related events
An increased incidence of AIDS-related events was found in patients with deeply reduced renal
function (eGFR<60 ml/min) as reported in Table 5. Incidence was 9.51 (95%CI 8.35–10.83),
6.04 (95%CI 4.74–7.71) and 25.0 (95%CI 15.96–39.22) per 1,000 PYFU, among patients with
Prognostic Value of Impaired Renal Function in HIV Infection
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Table 1. Characteristics of patients by baseline eGFR.
eGFR (CKD_Epi formula, ml/min/1.73m2)
Characteristics >90 89–60 <60 Total p-value
N = 5243 N = 1936 N = 206 N = 7385
Gender, n(%) <.001
Female 1327 (25.3%) 576 (29.8%) 58 (28.2%) 1961 (26.6%)
Mode of HIV Transmission, n(%) <.001
IDU 1263 (24.1%) 360 (18.6%) 34 (16.5%) 1657 (22.5%)
Homosexual contacts 1651 (31.5%) 593 (30.7%) 52 (25.2%) 2296 (31.1%)
Heterosexual contacts 2010 (38.3%) 865 (44.7%) 89 (43.2%) 2964 (40.1%)
Other/Unknown 315 (6.0%) 116 (6.0%) 31 (15.0%) 462 (6.3%)
Ethnicity, n(%) <.001
Black 273 (5.2%) 41 (2.1%) 14 (6.8%) 328 (4.4%)
AIDS diagnosis, n(%) <.001
Yes 600 (11.4%) 249 (12.9%) 60 (29.1%) 909 (12.3%)
CCVD diagnosis, n(%) <.001
Yes 375 (7.2%) 223 (11.5%) 56 (27.2%) 654 (8.9%)
HBsAg, n(%) 0.890
Negative 4122 (78.6%) 1536 (79.3%) 163 (79.1%) 5821 (78.8%)
Positive 230 (4.4%) 81 (4.2%) 11 (5.3%) 322 (4.4%)
Not tested 891 (17.0%) 319 (16.5%) 32 (15.5%) 1242 (16.8%)
HCVAb, n(%) <.001
Negative 3020 (57.6%) 1224 (63.2%) 122 (59.2%) 4366 (59.1%)
Positive 1368 (26.1%) 397 (20.5%) 45 (21.8%) 1810 (24.5%)
Not tested 855 (16.3%) 315 (16.3%) 39 (18.9%) 1209 (16.4%)
Hepatitis co-infection*, n(%) <.001
No 2780 (53.0%) 1129 (58.3%) 113 (54.9%) 4022 (54.5%)
Yes 1520 (29.0%) 456 (23.6%) 54 (26.2%) 2030 (27.5%)
Not tested 943 (18.0%) 351 (18.1%) 39 (18.9%) 1333 (18.1%)
Calendar year of baseline <.001
Median (IQR) 2004 (2002, 2009) 2003 (2002, 2009) 2006 (2003, 2010) 2004 (2002, 2009)
Age, years <.001
Median (IQR) 35 (30, 40) 39 (34, 48) 43 (37, 55) 36 (31, 42)
CD4 count, cells/mmc <.001
Median (IQR) 449 (288, 646) 453 (270, 660) 361 (124, 551) 447 (280, 647)
CD4 count nadir, cells/mmc <.001
Median (IQR) 348 (192, 514) 340 (175, 502) 200 (57, 400) 342 (183, 508)
CD8 count, cells/mmc 0.454
Median (IQR) 935 (662, 1288) 944 (654, 1297) 846 (544, 1362) 935 (658, 1291)
Viral load, log10 copies/mL 0.014
Median (IQR) 3.92 (2.43, 4.74) 3.82 (2.30, 4.68) 3.79 (1.70, 4.85) 3.89 (2.35, 4.73)
ART-naive, n(%) <.001
Yes 998 (24.8%) 422 (26.9%) 48 (28.6%) 1468 (25.5%)
Diabetes, n(%) <.001
Yes 84 (1.6%) 56 (2.9%) 16 (7.8%) 156 (2.1%)
Smoking, n(%) <.001
No 2071 (39.5%) 846 (43.7%) 104 (50.5%) 3021 (40.9%)
Yes 2463 (47.0%) 810 (41.8%) 73 (35.4%) 3346 (45.3%)
Unknown 709 (13.5%) 280 (14.5%) 29 (14.1%) 1018 (13.8%)
(Continued)
Prognostic Value of Impaired Renal Function in HIV Infection
PLOS ONE | DOI:10.1371/journal.pone.0124252 May 1, 2015 6 / 15
eGFR90, 60–89,<60 ml/min, respectively (Fig 2). Again, in the unadjusted analysis the inci-
dence rates among patients with reduced renal function (eGFR<60 ml/min) was significantly
higher than among HIV-infected subjects with normal renal function (eGFR90 ml/min),
with an unadjusted hazard ratio of 2.49 (95%CI 1.56–3.97). In contrast, HIV-infected subjects
with mild renal impairment (60eGFR<90 ml/min) showed decreased incidence rates of
HIV-related events as compared to patients with normal renal function (eGFR90 ml/min),
with an unadjusted hazard ratio of 0.68 (95% CI 0.52–0.90). Reduced renal function
(eGFR<60 ml/min) was independently associated with a higher risk of developing HIV-related
events (adjusted HR 2.49; 95%CI 1.56–3.97) in a multivariate model adjusted for baseline char-
acteristics (age, gender, mode of HIV transmission, nationality and calendar year of baseline)
but did not remain independently associated in a multivariate model adjusted for HIV-
associated characteristics (ART-status, baseline CD4+ and CD8+ T cell count, nadir CD4+ T
cell count, baseline HIV-RNA, co-infection with HBV/HCV). Interestingly, mild renal im-
pairment was confirmed to be an independent protective factor for HIV-related events (adjust-
ed HR 0.48; 95% CI 0.31–0.75) in the fully adjusted model.
Other co-variates which resulted independently associated with the risk of cardiovascular
events were: female gender (HR 1.64 versus male; 95%CI 1.12–2.42), ethnicity (HR 2.80 Black
versus Caucasian; 95%CI 1.49–5.27), previous AIDS diagnosis (HR 1.79; 95%CI 1.19–2.71),
baseline HIV-RNA level (HR 1.32 per log10 higher; 95%CI 1.14–1.53) and diabetes diagnosis
(HR 3.34 versus no diabetes diagnosis; 95%CI 1.40–7.97) (Table 6).
Discussion
In a large cohort of antiretroviral treatment-naïve patients seen for care in Italy and starting
ART, our primary goal was to evaluate the role of renal function measurement in predicting
Table 1. (Continued)
eGFR (CKD_Epi formula, ml/min/1.73m2)
Characteristics >90 89–60 <60 Total p-value
Total cholesterol, mg/dL <.001
Median (IQR) 167 (141, 196) 179 (150, 210) 179 (145, 215) 170 (143, 201)
HDL cholesterol, mg/dL 0.002
Median (IQR) 42 (34, 52) 42 (34, 53) 37 (29, 49) 42 (34, 52)
Use of statins, n(%) 0.001
Yes 75 (1.4%) 41 (2.1%) 9 (4.4%) 125 (1.7%)
Use of blood pressure lowering drugs, n(%) <.001
Yes 107 (2.0%) 96 (5.0%) 25 (12.1%) 228 (3.1%)
Follow-up, months <.001
Median (IQR) 40 (20, 86) 51 (24, 109) 31 (13, 57) 43 (21, 93)
Time from enrolment to first eGFR value,
months
0.494
Median (IQR) 2 (0, 51) 1 (0, 50) 1 (0, 44) 2 (0, 51)
egfr (CKD_Epi formula), ml/min/1.73m2 <.001
Median (IQR) 107.4 (98.87,
114.9)
80.73 (74.43,
85.41)
49.30 (31.35,
55.09)
100.7 (87.21,
111.7)
Blood glucose, mg/dL <.001
Median (IQR) 86 (80, 94) 88 (81, 96) 90 (80, 100) 87 (80, 95)
* HCVAb+ or HBsAg+
doi:10.1371/journal.pone.0124252.t001
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clinical events, especially cerebro-cardiovascular events, AIDS-related outcomes and even
death from both causes.
In the great majority of previously published reports [9–13], kidney disease has been
defined by classifying patients in two categories: those with eGFR<60 ml/min and those with
eGFR>60 ml/min; in contrast, our study additionally focuses on mild renal impairment, de-
fined as a 60>eGFR<90 ml/min, as before its predictive value has not been extensively investi-
gated despite its high prevalence in HIV- positive populations.
Indeed, while mild renal dysfunction (60<eGFR<90) is a relatively frequent condition in
our cohort of HIV-infected patients (26%), we found a low prevalence of severe renal im-
pairment (3% of population had eGFR<60ml/min) at baseline. This was anticipated as people
are a relatively healthy population enrolled when they are antiretroviral-naïve by study design.
Our study highlights the existence of a strong link between kidney function and CCVD risk
in HIV-infected individuals. Indeed, we observed a marked gradient in the association between
eGFR levels and the risk of cerebro-cardiovascular disease, with an intermediate excess of risk
of CCVD in patients with mild renal impairment (eGFR 60–89 ml/min) and a greater risk in
patients with severe chronic disease (eGFR< 60 ml/min). Importantly, we found that lower
eGFR was associated with a significantly increased risk of CCVD even after adjustment for
Table 2. Description of event-defining diseases.
Events Frequency
Cerebro-cardiovascular events 130
Coronaropathy 64 (49.2%)
Cerebro-vascular events 13 (10%)
Cardiomyopathy and heart failure 28 (21.5%)
Other major CCVD events (including coronary artery bypass graft, carotid endarterectomy,
or angioplasty)
14 (10%)
Death from CCVD events 11 (10%)
AIDS-defining events 311
AIDS-dementia complex 7 (2.7%)
Salmonella bacteremia, recurrent 1(0.3%)
Cervical cancer 15 (5.8%)
Oesophageal candidiasis 33 (12.7%)
Cryptococcosis, extrapulmonary 4 (1.5%)
Cryptosporidiosis 2 (0.7%)
Herpes simplex (bronchitis, pneumonia) 4 (1.5%)
Isosporiasis 1 (0.4%)
Histoplasmosis 2 (0.8%)
Non Hodgkin lymphoma 45 (14.5%)
Disseminated CMV infection 23 (8.8%)
Atypical mycobacteriosis 14 (5.4%)
Progressive multifocal leukoencephalopathy 6 (2.3%)
Recurrent pneumonia 7 (2.7%)
Pneumocystis jiroveci pneumonia 16 (6.1%)
Kaposi’s sarcoma 33 (12.7%)
Cerebral toxoplasmosi 9 (3.5%)
Tuberculosis 31 (11.9%)
Wasting syndrome 14 (5.4%)
Others 7 (2.7%)
doi:10.1371/journal.pone.0124252.t002
Prognostic Value of Impaired Renal Function in HIV Infection
PLOS ONE | DOI:10.1371/journal.pone.0124252 May 1, 2015 8 / 15
baseline demographic characteristics of patients, HIV-associated factors and traditional cardio-
vascular risk factors (smoking, diabetes, hypertension, use of lipid lowering drugs, total and
HDL cholesterol values, blood glucose levels). This held true both in the analysis using the cate-
gorical variable comparing different levels of renal impairment and in the analysis using eGFR
as continuous in the log scale.
Thus, our results confirm that reduced impaired renal function is an important risk factor
for cerebro-cardiovascular events in the HIV-population. As outlined above, one of the key
finding is that, compared to other studies investigating the association between kidney function
and the risk of CCVD9, this is the first to identify HIV-infected patients with mild renal
Table 3. Rates and hazard ratios of CVD associated with eGFR from fitting a Cox regression model.
Hazard Ratio (95% CI)
Baseline
eGFR
No. CVD
events
PYFU Rate/
1000PYFU
95% CI Unadjusted Adjusted(a) Adjusted(b) Adjusted(c) Adjusted(d)
>90 71 24412 2.91 2.30,
3.67
1.00 1.00 1.00 1.00 1.00
60–89 50 10799 4.63 3.51,
6.11
1.58 (1.10,
2.27)
1.18 (0.80,
1.74)
1.72 (1.11,
2.66)
1.63 (1.11,
2.40)
1.56 (0.96,
2.53)
<60 9 756.8 11.9 6.19,
22.85
4.14 (2.07,
8.29)
1.94 (0.93,
4.07)
1.44 (0.44,
4.73)
2.98 (1.28,
6.95)
1.04 (0.30,
3.57)
per log10
lower
5.32 (3.02,
9.38)
3.28 (1.47,
7.31)
3.71 (1.49,
9.28)
7.24 (3.05,
17.23)
3.11 (0.74,
13.13)
(a) Adjusted for age, gender mode of HIV transmission, ethnicity and calendar year of baseline
(b) Adjusted for smoking, diabetes mellitus,previous AIDS diagnosis, blood pressure lowering drugs,lipid lowering drugs, total cholesterol, blood glucose
levelsand high density lipoprotein cholesterol
(c) Adjusted for ART-status, baseline CD4, CD8, nadir CD4, baseline HIV-RNA and co-infection with hepatitis B/C
(d) Adjusted for factors in footnotes a-c.
doi:10.1371/journal.pone.0124252.t003
Fig 1. Risk of cerebro-cardiovascular disease during follow-up according to basal eGFR.
doi:10.1371/journal.pone.0124252.g001
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impairment (90<eGFR<60) as a population at increased risk of cerebro-cardiovascular mor-
bidity and mortality.
This result is however consistent with that of multiple studies conducted in general popula-
tion, which showed that kidney disease is associated with dyslipidemia, anemia, left ventricular
hypertrophy, arterial stiffness, inflammation and endothelial dysfunction [17].
Conversely, in our analysis, HIV-associated parameters do not seem to play a substantial
role in the development of CCVD events; indeed in our population only age and ethnicity were
independent markers of CCVD risk, while poor immunological condition, represented by CD4
cells count and CD4 cells nadir, did not predict cerebro-cardiovascular events. These finding
differ from other studies which found that lower CD4+ count, together with traditional CCVD
risk factors and duration of ART are associated with increased incidence of CCVD events [18–
19]. But recent data from D.A.D. And COHERE show the same thing i.e. That CD4 count does
not predict risk of MI and CVD events in general. This difference might be explained by the
characteristics of the patients in our cohort (CD4 count were high on average at the date in
Table 4. Hazard ratios of CCVD from fitting a Cox regression model (other factors).
Hazard Ratio of CCVD
Unadjusted Adjusted(e)
Gender: Female vs. male 0.97 (0.66, 1.43) 0.885 1.30 (0.75, 2.26) 0.346
Mode of HIV Transmission: Heterosexual contacts 1.00 1.00
IDU 0.92 (0.60, 1.41) 0.711 0.94 (0.44, 2.01) 0.869
Homosexual contacts 0.78 (0.50, 1.21) 0.267 0.92 (0.47, 1.77) 0.797
Other/Unknown 0.90 (0.41, 1.98) 0.796 0.94 (0.33, 2.70) 0.914
Ethnicity, Black vs. Caucasian 2.88 (1.51, 5.50) 0.001 4.82 (1.91, 12.16) <.001
CCVD diagnosis,Yes vs. No 3.07 (2.05, 4.60) <.001 1.35 (0.70, 2.60) 0.367
HBsAg, Negative 1.00 1.00
Positive 1.18 (0.80, 1.74) 0.398 1.70 (0.85, 3.37) 0.131
Not tested 1.13 (0.68, 1.88) 0.637 0.39 (0.11, 1.41) 0.152
HCVAb, Negative 1.00 1.00
Positive 1.18 (0.80, 1.74) 0.398 1.70 (0.85, 3.37) 0.131
Not tested 1.13 (0.68, 1.88) 0.637 0.39 (0.11, 1.41) 0.152
Calendar year of baseline per more recent 1.03 (0.98, 1.09) 0.246 0.97 (0.88, 1.07) 0.527
Age, years per 10 years older 1.90 (1.63, 2.21) <.001 1.78 (1.39, 2.30) <.001
CD4 count, cells/mmc per 100 higher 0.97 (0.91, 1.03) 0.280 1.06 (0.95, 1.19) 0.296
CD4 count nadir, cells/mmc per 100 higher 0.88 (0.81, 0.95) 0.001 0.86 (0.73, 1.01) 0.063
CD8 count, cells/mmc per 100 higher 1.00 (0.99, 1.01) 0.897 0.99 (0.96, 1.03) 0.703
Viral load, log10 copies/mL per log higher 0.94 (0.82, 1.07) 0.349 1.09 (0.89, 1.35) 0.392
ART-naive, Yes vs. No 0.66 (0.46, 0.95) 0.024 0.79 (0.43, 1.44) 0.437
Diabetes, Yes vs. No 1.81 (0.74, 4.43) 0.192 0.53 (0.15, 1.89) 0.329
Smoking, No 1.00 1.00
Yes 1.25 (0.85, 1.82) 0.253 1.41 (0.84, 2.36) 0.193
Unknown 0.80 (0.45, 1.42) 0.442 1.99 (0.73, 5.42) 0.180
Total cholesterol, mg/dL per 100 higher 1.42 (0.99, 2.03) 0.054 1.32 (0.79, 2.19) 0.290
HDL cholesterol, mg/dL per 100 higher 0.17 (0.04, 0.77) 0.022 0.19 (0.03, 1.13) 0.068
Use of statins, Yes vs. No 3.95 (2.00, 7.77) <.001 1.35 (0.50, 3.63) 0.552
Use of blood pressure lowering drugs, Yes vs. No 5.37 (3.22, 8.95) <.001 2.16 (0.96, 4.86) 0.062
Blood glucose, mg/dL per 100 higher 1.28 (0.66, 2.49) 0.470 0.83 (0.29, 2.41) 0.737
doi:10.1371/journal.pone.0124252.t004
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which the first eGFR was measured) and the analysis takes into account only baseline CD4
count and not the current value.
Our study highlights the importance of estimation of filtrate through creatinine measure-
ment as a clinical tool for identifying HIV-infected individuals at elevated risk for cerebro-car-
diovascular events, and strengthens the fact that managing traditional risk factors in HIV
population with renal impairment should be a priority.
Kidney disease is also feared as a predisposing condition for progression toward AIDS and
death. In our analysis, initial serious renal impairment (eGFR<60) seems to be associated with
an increase in number of AIDS related illnesses. However, this link was not confirmed after ad-
justment for the presence or history of antiretroviral treatment, CD4+ T cells nadir, baseline
CD4+ and CD8+ T cells count, and baseline HIV viral load together with chronic hepatitis
Table 5. Rates and hazard ratios of AIDS associated with eGFR from fitting a Cox regression model.
Hazard Ratio (95% CI)
Baseline
eGFR
No. AIDS
events
PYFU Rate/
1000PYFU
95% CI Unadjusted Adjusted(a) Adjusted(b) Adjusted(c) Adjusted(d)
>90 227 23880 9.51 8.35,
10.83
1.00 1.00 1.00 1.00 1.00
60–89 65 10754 6.04 4.74, 7.71 0.68 (0.52,
0.90)
0.68 (0.51,
0.90)
0.48 (0.32,
0.72)
0.64 (0.47,
0.88)
0.48 (0.31,
0.75)
<60 19 759.4 25.0 15.96,
39.22
2.49 (1.56,
3.97)
2.20 (1.35,
3.58)
1.71 (0.89,
3.30)
1.90 (1.12,
3.23)
1.26 (0.57,
2.81)
(a) Adjusted for age, gender mode of HIV transmission, ethnicity and calendar year of baseline
(b) Adjusted for smoking, diabetes mellitus,previous AIDS diagnosis, blood pressure lowering drugs,lipid lowering drugs, total cholesterol, blood glucose
levelsand high density lipoprotein cholesterol
(c) Adjusted for ART-status, baseline CD4, CD8, nadir CD4, baseline HIV-RNA and co-infection with hepatitis B/C
(d) Adjusted for factors in footnotes a-c.
doi:10.1371/journal.pone.0124252.t005
Fig 2. Risk of AIDS-events during follow-up according to basal eGFR.
doi:10.1371/journal.pone.0124252.g002
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co-infections. This is consistent with the results of Sczech et al who found that dipstick protein-
uria but not inverse creatinine was significantly associated with the development of AIDS-
defining illness [10]. Unfortunately dipstick proteinuria was not available for our patients. This
finding is suggestive for the many sided clinical picture of patients who usually develops AIDS
defining illnesses in which HIV-related parameters, as a mirror of immunological condition,
play a pivotal role in determining collapse toward AIDS development. On the other hand, ad-
vanced HIV disease is also associated with renal dysfunction and it is therefore a confounder
for the association between renal disease and risk of AIDS and AIDS-related death. All the pa-
rameters in our analysis have been measured concomitantly at baseline and therefore it is diffi-
cult to understand dynamic mechanisms that might have led to disease progression. Even in a
situation in which prospective measures of both creatinine and CD4 count are considered is
often difficult to establish links of causality. Nevertheless, it is conceivable that renal im-
pairment is likely to be a consequence and not the cause of a worse immunological situation.
Of interest, participants with mild dysfunction were at lower risk of HIV progression and the
association remained significant after controlling for a number of potential confounding
Table 6. Hazard ratios of AIDS from fitting a Cox regression model (other factors).
Hazard Ratio of AIDS
Unadjusted Adjusted(e)
Gender: Female vs. male 1.16 (0.91, 1.47) 0.242 1.64 (1.12, 2.42) 0.011
Mode of HIV Transmission: Heterosexual contacts 1.00 1.00
IDU 1.18 (0.90, 1.55) 0.222 1.66 (0.95, 2.88) 0.073
Homosexual contacts 0.83 (0.63, 1.11) 0.209 1.11 (0.69, 1.79) 0.658
Other/Unknown 0.88 (0.53, 1.49) 0.642 0.58 (0.23, 1.46) 0.249
Ethnicity, Black vs. Caucasian 2.25 (1.46, 3.47) <.001 2.80 (1.49, 5.27) 0.001
AIDS diagnosis,Yes vs. No 2.64 (2.05, 3.41) <.001 1.79 (1.19, 2.71) 0.006
HBsAg, Negative 1.00 1.00
Positive 1.45 (0.91, 2.31) 0.119 1.08 (0.54, 2.13) 0.831
Not tested 1.00 (0.74, 1.37) 0.983 0.81 (0.37, 1.76) 0.593
HCVAb, Negative 1.00 1.00
Positive 1.16 (0.90, 1.49) 0.257 0.97 (0.57, 1.65) 0.908
Not tested 0.94 (0.67, 1.31) 0.693 1.00 (0.44, 2.28) 0.993
Calendar year of baseline per more recent 1.04 (1.01, 1.07) 0.013 0.99 (0.93, 1.05) 0.651
Age, years per 10 years older 1.09 (0.97, 1.23) 0.131 1.05 (0.86, 1.27) 0.649
CD4 count, cells/mmc per 100 higher 0.78 (0.74, 0.82) <.001 0.93 (0.84, 1.04) 0.213
CD4 count nadir, cells/mmc per 100 higher 0.80 (0.75, 0.84) <.001 0.89 (0.77, 1.03) 0.110
CD8 count, cells/mmc per 100 higher 0.99 (0.98, 1.01) 0.495 1.00 (1.00, 1.00) 0.913
Viral load, log10 copies/mL per log higher 1.51 (1.37, 1.67) <.001 1.32 (1.14, 1.53) <.001
ART-naive, Yes vs. No 1.05 (0.84, 1.31) 0.691 1.09 (0.74, 1.61) 0.664
Diabetes, Yes vs. No 1.66 (0.91, 3.03) 0.098 3.34 (1.40, 7.97) 0.007
Smoking, No 1.00 1.00
Yes 1.01 (0.80, 1.28) 0.940 1.19 (0.83, 1.70) 0.349
Unknown 0.72 (0.50, 1.05) 0.090 0.93 (0.44, 1.97) 0.854
Total cholesterol, mg/dL per 100 higher 0.43 (0.32, 0.57) <.001 0.91 (0.61, 1.36) 0.640
HDL cholesterol, mg/dL per 100 higher 0.11 (0.04, 0.31) <.001 0.37 (0.11, 1.28) 0.117
Use of statins, Yes vs. No 0.17 (0.02, 1.18) 0.073 0.27 (0.04, 1.96) 0.196
Use of blood pressure lowering drugs, Yes vs. No 0.75 (0.36, 1.60) 0.461 0.52 (0.16, 1.67) 0.272
Blood glucose, mg/dL per 100 higher 1.32 (0.87, 2.01) 0.187 0.64 (0.31, 1.35) 0.246
doi:10.1371/journal.pone.0124252.t006
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factors. This might be due to the combined effect of low impact of renal disease on long term
HIV disease progression and the fact that these patients were more able to tolerate and respond
well to antiretroviral treatment. Some of this question might be answered by including time-
dependent confounding but more sophisticated methods than standard survival analysis are
needed to disentangle the complex confounding issue of time-dependent markers affected by
prior use of ART [20]
Our results, however, differ from those of other studies assessing and justifying the develop-
ment of renal abnormalities as predictors for AIDS progression [10–11]. Gupta et al, found
that lower renal function defined as eGFR< 60 ml/min was independently associated with an
increased risk of HIV disease progression [12]. Reasons for the discrepancy are unclear but
might be attributable to the different endpoint used (time to developing either a CD4 count
<200 cells/mm3 or WHO stage 3 or 4 disease) clinical setting, patients ethnicity or a combina-
tion of these.
In a recent analysis Lucas G et al evaluated the association of eGFR, estimated by three dif-
ferent equations (Cockcroft/Gault, MDRD and CKD-Epi with and withous the inclusion of
cystatin C besides creatinine), with clinical events in HIV-infected patients in the SMART
study and found that eGFR estimates using plasma cystatin C had stronger associations with
mortality, cardiovascular events and opportunistic diseases than eGFR based on plasma creati-
nine [21]. Indeed, one limit of our study is the unavailability of other markers of kidney dam-
age, expecially in patients with eGFR above 60 ml/min, for whom CKD-EPI, like other existing
GFR-estimating equations have increasing bias. Unfortunately, plasma cystatin C was not
available in our patients and its predictive value in patients receiving ART should be further
investigated.
In conclusion, in this large cohort of HIV-infected patients seen for care in Italy, we ob-
served a strong association between levels of eGFR and cerebro-cardiovascular diseases, while
severe renal impairment did not predict HIV-related events. A major strength of our study is
the analysis of the predictive role of mild renal impairment. It is important to increase our un-
derstanding of the mechanisms leading to severe non-AIDS morbidity anf mortality in the con-
text of the emerging clinical challenge of treating an ageing HIV-infected population. These
results may improve clinical management of HIV-infected patients by helping clinicians in
identifyng people at higher risk of CCVD and provide a rationale for the evaluation of thera-
peutic strategies aimed to ameliorate patients' CCVD risk profile.
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